Embecta Corp
$ 4.42
26.29%
07 Aug - close price
- Market Cap 211,800,000 USD
- Current Price $ 4.42
- High / Low $ 4.69 / 3.96
- Stock P/E 2.03
- Book Value -10.55
- EPS 1.76
- Next Earning Report -
- Dividend Per Share $0.60
- Dividend Yield 15.7 %
- Next Dividend Date -
- ROA 0.17 %
- ROE N/A %
- 52 Week High 15.08
- 52 Week Low 2.76
About
Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
Analyst Target Price
$4.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-07 | 2026-05-05 | 2026-02-05 | 2025-11-25 | 2025-08-08 | 2025-05-09 | 2025-02-06 | 2024-11-26 | 2024-08-09 | 2024-05-09 | 2024-02-09 | 2023-11-21 |
| Reported EPS | 1.12 | 0.27 | 0.71 | 0.5 | 1.12 | 0.7 | 0.65 | 0.45 | 0.74 | 0.67 | 0.61 | 0.59 |
| Estimated EPS | 0.26 | 0.42 | 0.67 | 0.46 | 0.78 | 0.59 | 0.44 | 0.36 | 0.46 | 0.4 | 0.46 | 0.4 |
| Surprise | 0.86 | -0.15 | 0.04 | 0.04 | 0.34 | 0.11 | 0.21 | 0.09 | 0.28 | 0.27 | 0.15 | 0.19 |
| Surprise Percentage | 330.7692% | -35.7143% | 5.9701% | 8.6957% | 43.5897% | 18.6441% | 47.7273% | 25% | 60.8696% | 67.5% | 32.6087% | 47.5% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-09-15 | 2026-06-15 | 2026-03-17 | 2025-12-18 | 2025-09-15 | 2025-06-13 | 2025-03-14 | 2024-12-18 | 2024-09-13 | 2024-06-14 |
| Amount | $0.01 | $0.01 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 | $0.15 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EMBC
2026-08-07 20:12:46
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026 deadline to seek lead plaintiff status in a securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly its pen needle business, which led to a significant stock price drop after missing Q2 2026 fiscal results and cutting full-year guidance. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and suffered losses, are encouraged to contact the firm.
2026-08-07 19:12:46
Embecta Corp (EMBC) reported a strong sequential recovery in Q3 fiscal 2026, with revenue increasing by approximately $50 million and adjusted operating income rising by about $21 million compared to Q2. The company raised its fiscal 2026 adjusted operating margin guidance to 23.5%-24% and adjusted EPS guidance to $1.80-$1.90, attributing this to cost optimization efforts and the successful integration of the Owen Mumford acquisition. Despite a year-over-year revenue decline, particularly in the U.S., international business showed strong growth, and the company continues to focus on debt reduction and new product developments to combat competitive pressures.
2026-08-07 19:12:45
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Embecta Corp. (EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit follows a significant drop in Embecta's stock price after the company reported disappointing Q2 2026 financial results and reduced its fiscal 2026 revenue guidance. Investors have until August 17, 2026, to move the court to serve as a lead plaintiff.
2026-08-07 18:12:45
Embecta Corp. (EMBC) reported a significant decline in Q3 2026 profits and revenue, with net income falling 53.6% to $21.1 million and revenue decreasing by 8.1% to $271.7 million, largely due to lower pricing and volumes. The company completed the $208.0 million acquisition of Owen Mumford, which contributed $13.8 million in revenue, and made significant changes to its financial structure, including reducing its revolving credit commitments and decreasing its quarterly dividend. Embecta is also facing a securities class action lawsuit related to its fiscal 2026 revenue guidance.
2026-08-07 18:12:45
Embecta Corp. reported its 2026 quarter results with revenue of $271.7 million and diluted EPS of $0.36, marking a significant decrease from the prior year. The revenue decline was attributed to lower volume and pricing pressure, despite the acquisition of Owen Mumford. The company is responding to market shifts by reviewing its cost structure, expanding into B2B drug-delivery, and building inventory to prevent supply disruptions.
2026-08-07 11:10:52
Embecta (EMBC) reported its Q3 FY2026 financial results, achieving revenues of $271.7 million and a GAAP net income of $21.1 million. The company posted adjusted diluted EPS of $0.56 and has raised its full-year adjusted operating margin and adjusted EPS guidance, while reaffirming full-year revenue guidance. Key business highlights include the acquisition of Owen Mumford, growth in international revenues, and progress in product portfolio and B2B co-packaging expansions.
